Key Takeaways A Japanese health ministry panel backed full approval of Stemirac, a bone marrow cell therapy, on 15 October 2026. Reported data compared 73 treated patients with 66 untreated patients, and 40 treated patients improved in motor function. Treated patients received more rehabilitation, so it’s hard to isolate the
Key Takeaways Researchers test stem cell therapies for heart failure, but no trial shows that the cells rebuild a damaged heart. A 2016 Cochrane review of 38 trials and 1,907 people found no gain in heart pumping strength and rated the evidence low quality. A 2012 trial of 30 people
Key Takeaways Mesenchymal stem cell (MSC) therapy has been tested in small human trials for chronic lung inflammation, but none show it reverses lung scarring. A 2013 randomized trial of 62 people with chronic obstructive pulmonary disease (COPD) found no lung function gain from infused MSCs. A 2020 randomized trial
Key Takeaways The liver can repair itself to a point, but chronic liver diseases like cirrhosis eventually overwhelm that natural ability. Mesenchymal stem cell therapy is being studied as a supportive option, working mainly through anti inflammatory and immune-calming effects. One randomized trial found a real survival benefit in patients
Key Takeaways Mesenchymal stem cells MSCs are the main type of stem cell studied for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis. The largest controlled trial found stem cell infusions safe and effective to receive, but did not show clear improving lung function results overall. A smaller trial using
Key Takeaways Stem cell treatment for congestive heart failure targets the weak heart muscle directly, rather than just managing symptoms. Mesenchymal stem cells MSCs release growth factors that support cardiac repair, reduce inflammation, and may promote the growth of new blood vessels in the heart. Clinical trials and clinical studies
Quick Summary A 2026 Nature study (MATCH trial) shows autologous macrophage therapy may improve transplant‑free survival in cirrhosis. After 4 years, ~70% of treated patients were alive without liver transplant vs. ~40% in standard care. The treatment uses the patient’s own immune cells (macrophages) to reduce inflammation and support repair.
Quick Summary Family support is essential for recovery after cell-based therapy for hypoxic brain damage. Families help with daily rehabilitation exercises, motor function practice, medication schedules, and emotional support. Recovery takes months or years, and consistent family involvement improves both short-term and long-term neurological outcomes alongside treatments like mesenchymal stem
Quick Summary Mesenchymal stem cell (MSC) therapy for IBD (Crohn’s disease and ulcerative colitis) reduces inflammation, supports repair of damaged intestinal tissue, and helps balance immune response. It is not a replacement for biologics or steroids but may work alongside them. Clinical trials show improved gut symptoms and mucosal healing
Quick Summary Stem cell therapy for autism aims to reduce brain inflammation, modulate the immune system, and support nerve cell communication. Types of stem cells studied include umbilical cord derived cells, bone marrow stem cells, and umbilical cord blood cells. Early clinical trials show potential improvements in social interaction and
